INVO Bioscience (INVO) Competitors $2.10 -0.10 (-4.55%) As of 04/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock INVO vs. DXR, FEMY, GBS, NMTC, DRIO, PYPD, MDAI, RVP, VVOS, and NXGLShould you be buying INVO Bioscience stock or one of its competitors? The main competitors of INVO Bioscience include Daxor (DXR), Femasys (FEMY), GBS (GBS), NeuroOne Medical Technologies (NMTC), DarioHealth (DRIO), PolyPid (PYPD), Spectral AI (MDAI), Retractable Technologies (RVP), Vivos Therapeutics (VVOS), and NEXGEL (NXGL). These companies are all part of the "surgical & medical instruments" industry. INVO Bioscience vs. Daxor Femasys GBS NeuroOne Medical Technologies DarioHealth PolyPid Spectral AI Retractable Technologies Vivos Therapeutics NEXGEL Daxor (NASDAQ:DXR) and INVO Bioscience (NASDAQ:INVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Does the MarketBeat Community believe in DXR or INVO? INVO Bioscience received 5 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 46.67% of users gave INVO Bioscience an outperform vote. CompanyUnderperformOutperformDaxorOutperform Votes2100.00% Underperform VotesNo VotesINVO BioscienceOutperform Votes746.67% Underperform Votes853.33% Does the media prefer DXR or INVO? In the previous week, Daxor had 2 more articles in the media than INVO Bioscience. MarketBeat recorded 2 mentions for Daxor and 0 mentions for INVO Bioscience. Daxor's average media sentiment score of 0.00 equaled INVO Bioscience'saverage media sentiment score. Company Overall Sentiment Daxor Neutral INVO Bioscience Neutral Do institutionals & insiders have more ownership in DXR or INVO? 1.3% of Daxor shares are owned by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are owned by institutional investors. 59.0% of Daxor shares are owned by insiders. Comparatively, 3.5% of INVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, DXR or INVO? Daxor has higher earnings, but lower revenue than INVO Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaxor$2.13M17.37N/AN/AN/AINVO Bioscience$5.77M1.39-$8.03MN/AN/A Do analysts recommend DXR or INVO? Daxor presently has a consensus price target of $25.00, indicating a potential upside of 226.80%. Given Daxor's stronger consensus rating and higher possible upside, equities research analysts plainly believe Daxor is more favorable than INVO Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00INVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is DXR or INVO more profitable? Daxor has a net margin of 0.00% compared to INVO Bioscience's net margin of -122.79%. Company Net Margins Return on Equity Return on Assets DaxorN/A N/A N/A INVO Bioscience -122.79%N/A -36.94% Which has more risk and volatility, DXR or INVO? Daxor has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. SummaryDaxor beats INVO Bioscience on 9 of the 13 factors compared between the two stocks. Remove Ads Get INVO Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for INVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INVO vs. The Competition Export to ExcelMetricINVO BioscienceSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.00M$4.06B$5.33B$7.16BDividend YieldN/A37.84%4.87%4.06%P/E RatioN/A27.5222.9417.50Price / Sales1.3945.28357.9385.03Price / CashN/A51.0838.1634.64Price / Book-1.025.706.263.82Net Income-$8.03M$67.64M$3.21B$247.19M7 Day Performance-11.76%-8.68%-7.86%-7.19%1 Month Performance466.04%-8.36%-2.83%-9.97%1 Year Performance141.38%5.40%3.74%-7.26% INVO Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INVOINVO BioscienceN/A$2.10-4.5%N/A+139.2%$8.00M$5.77M0.0025DXRDaxor3.1976 of 5 stars$8.15-2.2%$25.00+206.7%-12.9%$39.42M$2.13M0.0037FEMYFemasys2.3413 of 5 stars$1.56-2.5%$11.50+637.2%-32.0%$35.72M$1.26M-1.9330GBSGBSN/A$2.16+3.3%N/A-61.7%$32.16M$440,000.00-3.867NMTCNeuroOne Medical Technologies0.4974 of 5 stars$0.97-5.8%N/A-31.7%$29.94M$5.75M-3.7320News CoverageGap DownDRIODarioHealth1.8528 of 5 stars$0.70+1.7%$1.50+114.3%-59.7%$29.10M$27.04M-0.74200PYPDPolyPid2.2933 of 5 stars$2.94+4.4%$11.33+286.1%-43.4%$28.64MN/A-0.5980Gap DownMDAISpectral AI2.9456 of 5 stars$1.49-12.4%$4.75+218.8%-50.2%$27.70M$27.26M-2.2983Analyst ForecastShort Interest ↓Analyst RevisionGap DownHigh Trading VolumeRVPRetractable TechnologiesN/A$0.75+0.4%N/A-38.7%$22.55M$38.27M-1.39240Analyst ForecastGap DownVVOSVivos Therapeutics2.4479 of 5 stars$3.71+3.1%$6.30+69.8%-14.6%$21.85M$14.58M-0.65160Gap DownNXGLNEXGEL0.6501 of 5 stars$3.09+14.4%N/A+15.1%$20.98M$6.73M-5.3310Upcoming EarningsGap Up Remove Ads Related Companies and Tools Related Companies Daxor Competitors Femasys Competitors GBS Competitors NeuroOne Medical Technologies Competitors DarioHealth Competitors PolyPid Competitors Spectral AI Competitors Retractable Technologies Competitors Vivos Therapeutics Competitors NEXGEL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INVO) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INVO Stock Free INVO Stock Alerts